wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q36716682-09A972EF-63E8-4E76-8E45-0E40FC7E4D63
Q36716682-09A972EF-63E8-4E76-8E45-0E40FC7E4D63
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36716682-09A972EF-63E8-4E76-8E45-0E40FC7E4D63
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
P2860
Q36716682-09A972EF-63E8-4E76-8E45-0E40FC7E4D63
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36716682-09A972EF-63E8-4E76-8E45-0E40FC7E4D63
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5e83b6141805e3b7bdf0a847e5bc42a6b8b6dfdf
P2860
A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.